Cerus (CERS) Income from Non-Controlling Interests (2022 - 2026)
Cerus (CERS) reported Income from Non-Controlling Interests of -$8000.0 for Q1 2026, down 700.0% on a YoY basis from $1333.3 in Q1 2025, and down 700.0% sequentially from -$1000.0 in Q3 2025.
Cerus (CERS) Income from Non-Controlling Interests (2022 - 2026) Analysis & Trends
Cerus (CERS) has 5 years of Income from Non-Controlling Interests data on file, last reported at -$8000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Non-Controlling Interests fell 700.0% year-over-year to -$8000.0; the trailing twelve-month figure through Mar 2026 stood at -$17000.0 (up 59.52% YoY), and the FY2025 full-year result was -$10000.0, up 76.74% from the prior year.
- Income from Non-Controlling Interests eased to -$8000.0 in Q1 2026, from -$1000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of -$1000.0 in Q4 2022 to a low of -$61000.0 in Q4 2023.
- A 5-year average of -$20384.6 and a median of -$8000.0 in 2025 frame the typical range for Income from Non-Controlling Interests.
- Across the five-year window, Income from Non-Controlling Interests sank 6000.0% in 2023 and jumped 90.91% in 2024, its largest moves.
- Tracing CERS's Income from Non-Controlling Interests over 5 years: stood at -$1000.0 in 2022, then slumped by 6000.0% to -$61000.0 in 2023, then soared by 32.79% to -$41000.0 in 2024, then jumped by 97.56% to -$1000.0 in 2025, then plunged by 700.0% to -$8000.0 in 2026.
- Business Quant data shows CERS's Income from Non-Controlling Interests at -$8000.0 in Q1 2026, -$1000.0 in Q3 2025, and -$8000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.52 Bn | 176.22 Bn | 6.27 Bn | - |
| 2 | Stryker | 128.83 Bn | 125.95 Bn | 3.81 Bn | - |
| 3 | Medtronic | 108.61 Bn | 99.39 Bn | 6.41 Bn | 16.00 Mn |
| 4 | Boston Scientific | 68.35 Bn | 66.90 Bn | 3.61 Bn | -2.00 Mn |
| 5 | Edwards Lifesciences | 48.53 Bn | 44.86 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.42 Bn | 27.30 Bn | 750.30 Mn | - |
| 7 | GE HealthCare Technologies | 28.34 Bn | 26.06 Bn | 1.98 Bn | 22.00 Mn |
| 8 | Smith & Nephew | 26.92 Bn | 26.35 Bn | - | - |
| 9 | Koninklijke Philips | 25.49 Bn | 22.36 Bn | 2.07 Bn | -5.85 Mn |
| 10 | Cerus | 601.88 Mn | 521.45 Mn | 27.89 Mn | -8,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Jun 30, 2025 | -8,000.00 |
| Mar 31, 2025 | -1,000.00 |
| Dec 31, 2024 | -41,000.00 |
| Mar 31, 2024 | -2,000.00 |
| Dec 31, 2023 | -61,000.00 |
| Sep 30, 2023 | -19,000.00 |
| Jun 30, 2023 | -56,000.00 |
| Mar 31, 2023 | -22,000.00 |
| Dec 31, 2022 | -1,000.00 |
| Sep 30, 2022 | -39,000.00 |
| Jun 30, 2022 | -6,000.00 |